According to a recent LinkedIn post from C8 Health, the company is highlighting research presented at the American Society of Regional Anesthesia (ASRA) involving its artificial intelligence technology. The study reportedly compared neuraxial anticoagulation protocols from five hospitals against 96 recommendations from ASRA’s 5th edition guidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that over 60% of protocol items reviewed were either inconsistent with or missing from the guideline set, with better alignment in long-established, higher-evidence areas and weaker alignment in newer or lower-evidence topics such as specific drug thresholds and timing. This characterization points to both risk in current clinical practice and an opportunity for systematic protocol updates.
According to the post, the AI used in the research forms the basis of a forthcoming functionality called Evidence Compare, which C8 Health plans to introduce on its platform later this year. The post also references collaboration with the American Society of Anesthesiologists (ASA), which may support validation and adoption if these relationships translate into broader clinical engagement.
For investors, the described capability to identify guideline gaps at scale could enhance C8 Health’s value proposition in quality improvement and clinical decision support within anesthesiology and perioperative care. If Evidence Compare gains traction with hospitals and professional societies, it may strengthen the company’s competitive positioning in evidence-based protocol management and support future commercialization and partnership opportunities.